Novo Nordisk announced the results of its SOUL cardiovascular outcomes trial, which evaluated the effectiveness of oral semaglutide in reducing major adverse cardiovascular events (MACE) in adults with type 2 diabetes. The trial demonstrated a 14% reduction in the risk of MACE for those taking oral semaglutide compared to a placebo. The study enrolled 9,650 participants with established cardiovascular disease (CVD) or chronic kidney disease (CKD). Novo Nordisk plans to seek regulatory approval for a label expansion for Rybelsus® in the US and EU by early 2025, with the detailed results to be presented at a scientific conference next year.

For more information, visit BioSpace or Fierce Pharma.